HIFs (Hypoxia-inducible factors) are transcription factors that react to variations in the amount of oxygen available to cells, more specifically, to reductions in oxygen, or hypoxia. The effects of hypoxia, a condition of low oxygen concentration, on the cell are mediated by the HIF signaling cascade. Oftentimes, hypoxia prevents cells from differentiating. However, hypoxia encourages the growth of blood vessels and is crucial for the development of a vascular system in both cancer tumors and embryos.Additionally, the hypoxia in wounds encourages keratinocyte migration and epithelium repair. HIFs are essential to development in general. HIF-1 gene deletion in mammals causes perinatal death. It has been demonstrated that HIF-1 is essential for chondrocyte survival and enables the cells to adapt to low oxygen environments in the growth plates of bones. Human metabolism is controlled in large part by HIF. A number of medications that function as selective HIF prolyl hydroxylase inhibitors have recently been created.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V3444 | JNJ-42041935 | 1193383-09-3 | JNJ-42041935 is a novel, potent, competitive, reversible, and selective inhibitor of prolyl hydroxylasePHDwithpKivalues of 7.91±0.04, 7.29 ±0.05, and 7.65±0.09 for PHD1, PHD2, and PHD3, respectively. |
|
V51631 | KG-548 | 175205-09-1 | KG-548 is an ARNT/TACC3 interferon and HIF-1α. |
|
V2781 | LW6 | 934593-90-5 | LW6 is a hypoxia-inducible factor 1 (HIF) inhibitor which potently inhibits HIF-1α accumulation by degrading HIF-1α without affecting the HIF-1a mRNA levels during hypoxia. |
|
V4021 | ML228 | 1357171-62-0 | ML228 (ML-228; CID-46742353) is an activator of the Hypoxia Inducible Factor (HIF) which potently activate HIF in vitro as well as its downstream target VEGF. |
|
V73839 | ML228 analog | 1357026-36-8 | ML228 analog is the analog of ML228. |
|
V2958 | Molidustat | 1154028-82-6 | Molidustat (formerly known as BAY 85-3934) is a novel potent inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) which stimulates erythropoietin (EPO) production and the formation of red blood cells. |
|
V51639 | Moracin O | 123702-97-6 | Moracin O comes from Morus alba Linn. |
|
V51640 | Moracin P | 102841-46-3 | Moracin P is a 2-arylbenzoepoxy resin extracted from Mori Cortex Radicis. |
|
V51625 | Naphthofluorescein (Naphthafluorescein) | 61419-02-1 | Naphthylfluorescein inhibits the response between HIF-1 and Mint3. |
|
V51642 | OHM-1 | 1450995-09-1 | OHM1 is an analog of HIF1α CTAD and inhibits its binding to p300/CBP. |
|
V51622 | Oltipraz-d3 | 2012598-51-3 | Oltipraz-d3 is a labeled substitute for Oltipraz. |
|
V30464 | Oroxylin A | 480-11-5 | Oroxylin A is an active flavonoid compound with strong anti-cancer effects. |
|
V73835 | PHD-IN-1 | 2924182-31-8 | PHD-IN-1 (compound 80) is a potent PHD2 inhibitor (antagonist) with IC50 ≤5 nM. |
|
V73836 | PHD-IN-2 | 2924182-42-1 | PHD-IN-2 (Compound 91) is a PHD antagonist (IC50= <5 nM). |
|
V84840 | PHD-IN-3 | 2924181-77-9 | |
|
V73837 | PHD2-IN-1 | 2768219-28-7 | PHD2-IN-1 is a potent, orally bioactive HIF-prolyl hydroxylase 2 (PHD2) inhibitor (antagonist) with IC50 of 22.53 nM for anemia research. |
|
V84812 | PRLX-93936 dihydrochloride | 1094210-96-4 | |
|
V4090 | PT-2385 | 1672665-49-4 | PT2385 (PT-2385) is a nove, potent, selective and orally bioactive inhibitor of hypoxia inducible factor (HIF-2α) with anticancer and anti-hepatic steatosis activity. |
|
V51634 | Steppogenin | 56486-94-3 | Steppogenin is a potent HIF-1α and DLL4 replacement with IC50s of 0.56 and 8.46 μM, respectively. |
|
V51623 | TAT-cyclo-CLLFVY | 1446322-66-2 | TAT-cyclo-CLLFVY is a HIF-1 heterodimeric cyclic peptide conjugate that can inhibit regulatory hypoxia signaling activation. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
